$15.49
0.91% yesterday
Nasdaq, Nov 17, 10:00 pm CET
ISIN
CA05156V1022
Symbol
AUPH

Aurinia Pharmaceuticals Inc. Stock price

$15.49
+3.94 34.11% 1M
+7.42 91.95% 6M
+6.51 72.49% YTD
+7.48 93.38% 1Y
+10.75 226.79% 3Y
+1.94 14.32% 5Y
+12.79 473.70% 10Y
-59.76 79.42% 20Y
Nasdaq, Closing price Mon, Nov 17 2025
+0.14 0.91%
ISIN
CA05156V1022
Symbol
AUPH
Industry

New AI Insights on Aurinia Pharmaceuticals Inc. Insights AI Insights on Aurinia Pharmaceuticals Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$1.8b
Net debt
positive
Cash
$351.5m
Shares outstanding
131.8m
Valuation (TTM | estimate)
P/E
27.7 | 23.2
P/S
7.7 | 7.3
EV/Sales
6.6 | 6.3
EV/FCF
14.7
P/B
5.6
Financial Health
Equity Ratio
68.6%
Return on Equity
1.5%
ROCE
19.3%
ROIC
51.4%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$265.8m | $275.9m
EBITDA
$106.5m | $108.4m
EBIT
$87.0m | $92.5m
Net Income
$77.8m | $87.2m
Free Cash Flow
$119.9m
Growth (TTM | estimate)
Revenue
20.6% | 17.3%
EBITDA
2,067.7% | 186.4%
EBIT
448.9% | 401.9%
Net Income
445.2% | 1,416.4%
Free Cash Flow
323.6%
Margin (TTM | estimate)
Gross
88.9%
EBITDA
40.1% | 39.3%
EBIT
32.7%
Net
29.3% | 31.6%
Free Cash Flow
45.1%
More
EPS
$0.6
FCF per Share
$0.9
Short interest
6.9%
Employees
130
Rev per Employee
$1.8m
Show more

Is Aurinia Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Aurinia Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

Buy
85%
Hold
15%

Financial data from Aurinia Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
266 266
21% 21%
100%
- Direct Costs 29 29
5% 5%
11%
236 236
23% 23%
89%
- Selling and Administrative Expenses 110 110
41% 41%
41%
- Research and Development Expense 30 30
30% 30%
11%
106 106
2,068% 2,068%
40%
- Depreciation and Amortization 19 19
0% 0%
7%
EBIT (Operating Income) EBIT 87 87
449% 449%
33%
Net Profit 78 78
445% 445%
29%

In millions USD.

Don't miss a Thing! We will send you all news about Aurinia Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aurinia Pharmaceuticals Inc. Stock News

Neutral
Seeking Alpha
14 days ago
Aurinia Pharmaceuticals Inc. ( AUPH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Peter Greenleaf - President, CEO & Director Joseph Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Resear...
Neutral
Business Wire
14 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2025, total revenue was $73.5 million and $205.9 million, up 8% and 17%, re...
Neutral
Seeking Alpha
15 days ago
Aurinia Pharmaceuticals (AUPH) files a federal lawsuit against FDA's George Tidmarsh for alleged false statements about its lupus nephritis drug. Baidu's (BIDU) Apollo Go robotaxi service matches Waymo's weekly ride volume, while Pony AI (PONY) prepares for a major Hong Kong IPO.
More Aurinia Pharmaceuticals Inc. News

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Head office Canada
CEO Peter Greenleaf
Employees 130
Founded 1993
Website www.auriniapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today